by OTMS Staff | Mar 27, 2026 | Legal Reports
PatentVest Pulse Using AI In Your Inventive Process? Proceed to Patent, But Carefully Article | March 2026 The U.S. Patent and Trademark Office has sent a clear message to innovators: inventions involving AI may be patentable, including in biotech and healthcare, but...
by OTMS Staff | Mar 25, 2026 | PatentVest Pulse
PatentVest Pulse — The Amylin RenaissancePATENTVEST PULSEThe Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity MedicineReport #2 | March 2026GLP-1 receptor agonists built a $71 billion market by making patients...
by OTMS Staff | Feb 25, 2026 | PatentVest Pulse
Author: Tyler Teske Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don’t work, but because needles, cold chains, and $1,000-per-month...
by OTMS Staff | Feb 5, 2026 | Uncategorized
Author: Sarah Cork, Ph.D. Early-stage biotech companies generally understand that intellectual property management, in particular, patenting their crown-jewel technology, is a critical component of sound business strategy. But how might investment in the...
by OTMS Staff | Jan 13, 2026 | Uncategorized
Authors: Tyler Teske, Will Rosellini Executive Summary Where Value Will Actually Be Captured in the $1.8 Trillion Space Economy The global space economy represents a transformative $1.8 trillion opportunity at a critical inflection point. Driven by collapsing launch...
Recent Comments